At Pharminox our strategy for innovation is simple - we bring together creative chemistry, developmental pharmacology and validated cancer screening to identify potential development candidates and their clinical targets.

Our world class chemistry team has a strong track record in the discovery of new cancer therapies, including temozolomide, which is now a leading treatment for brain cancer. In addition to temozolomide, the team has been responsible for originating the marketed drug bropirimine, and for progressing four further anti-cancer agents into clinical trials.

Our chemistry driven approach is focused on discovering novel molecules which are patentable, synthetically accessible, and which we can predict will possess promising pharmaceutical properties.

All our compounds undergo internal biological screening for activity against human tumours before being sent to the US National Cancer Institute (NCI) for testing in the NCI's own rigorous in vitro screening programmes. Compounds showing a significant and unusual pattern of activity in these screens become the subject of integrated medicinal and computational chemistry as part of the process of lead optimisation undertaken by our team. In parallel these compounds are compared to an NCI database containing hundreds of thousands of profiled compounds, as the first step in target identification and subsequent in-house mechanistic evaluation.